Clinical trials: Rabies Post-exposure Prophylaxis
- Condition Rabies Post-exposure Prophylaxis
- Age group Children (under 18)
- Accepts healthy volunteers yes
Rabies
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children…
- Trial name
- NCT00708084
- Testing
- CL184, HRIG
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Virus Diseases, Rabies
A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.
The aim of this study is to evaluate the long-term (up to approx.10 years) persistence and to assess the boostability of immune responses in participants who received a primary series of accelerated or conventional rabies PrEP IM…
- Trial name
- NCT02545517
- Testing
- Rabipur, Blood sampling, Purified Chick-Embryo Cell Rabies Vaccine
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies (Healthy Volunteers)
Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland
Primary Objective: To describe the immune response induced by VRVg-2 and Verorab vaccine at Day 14 (to assess the immune response after 3 doses [2-2-2]) and Day 42 (to assess the immune response after 4 doses [2-2-2-0-2]) when…
- Trial name
- NCT04478084
- Testing
- Purified vero rabies vaccine - serum free VRVg-2, Purified inactivated rabies vaccine, Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)
- Where
- 3 sites in Thailand
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies Post-exposure Prophylaxis
Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia
A rabies virus neutralizing antibody (RVNA) concentration ≥ 0.5 IU/ml at 14 days after immunization is considered a proxy for protection in vaccine efficacy studies.
- Trial name
- NCT05684185
- Testing
- Intramuscular (IM) rabies post-exposure prophylaxis, Intradermal (ID) rabies post-exposure prophylaxis
- Where
- Cambodia
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Rabies Prevention
Early Rabies Vaccine Immunization in Primary School Children
700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose of 0.1mL into the skin in the deltoid region.
- Trial name
- I49P1 (NCT01107275)
- Testing
- rabies vaccine
- Where
- Thailand
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Provincial Public Health Office, Phetchabun
Virus Diseases
A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children
The purpose of this study is to evaluate the long-term persistence of immune responses approximately 5 years or more after simulated rabies post-exposure prophylaxis provided in 2012 according to Essen (1-1-1-1-1) or Zagreb…
- Trial name
- NCT02991872
- Testing
- Blood draw
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies Post-exposure Prophylaxis
SYN023 With Rabies Vaccine in Healthy Pediatric Subjects
This study is a randomized, double-blind, active-controlled design. The goal is to evaluate the safety, pharmacokinetics and pharmacodynamic of SYN023 in combination with rabies vaccine in healthy participants under 18 years of…
- Trial name
- NCT07342257
- Testing
- SYN023, Rabies Vaccine, HRIG
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Rabies (Healthy Volunteers)
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after post-exposure prophylaxis (PEP) vaccination, and to confirm its satisfying safety profile in the…
- Trial name
- NCT07055893
- Testing
- Rabies vaccine, Verorab®
- Where
- Pakistan
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Virus Diseases
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
The purpose of this study is to evaluate the 1 year immunogenicity persistence of Rabipur in children 6-17 years of age, and compare the Zagreb regimen with the Essen regimen.
- Trial name
- NCT03192371
- Testing
- Rabipur
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies Post-exposure Prophylaxis
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
- Trial name
- NCT00345319
- Testing
- rabies vaccine
- Where
- China
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Healthy Volunteers (Rabies Immunization)
Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year
The primary objective of the study is to demonstrate that a short intramuscular (IM) pre-exposure prophylaxis (PrEP) regimen is non-inferior to the reference IM PrEP regimen in terms of seroconversion rate.
- Trial name
- VAJ00001 (NCT03700242)
- Testing
- HDCV, PVRV
- Where
- 2 sites in Philippines
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immunity Persistence After Abridged Intradermal Rabies PEP
After exposure, rabies can be prevented in almost 100% of cases by the administration of sufficient and timely post-exposure prophylaxis (PEP).
- Trial name
- RESIST-3 (NCT04829630)
- Testing
- rabies vaccine
- Where
- 2 sites in Cambodia, Madagascar
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur